DarioHealth Corp. (DRIO) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 10.45M USD | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | (m) | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -31.83M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $10.45M | (m) | (m) | $-31.83M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $12.07M | (m) | (m) | $-34.55M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $13.79M | (m) | (m) | $-36.66M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $16.44M | (m) | (m) | $-39.76M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $18.56M | (m) | (m) | $-42.31M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $21.64M | (m) | (m) | $-49.30M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $24.18M | (m) | $46.00K | $-57.74M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $23.09M | (m) | (m) | $-60.29M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $23.31M | (m) | (m) | $-63.81M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $21.73M | (m) | (m) | $-61.64M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $20.25M | (m) | (m) | $-56.19M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $20.83M | (m) | (m) | $-50.98M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $19.97M | (m) | (m) | $-50.01M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $18.89M | (m) | (m) | $-53.35M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $19.65M | (m) | (m) | $-56.81M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $20.18M | (m) | (m) | $-69.47M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $20.89M | (m) | (m) | $-77.39M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $20.49M | (m) | (m) | $-78.04M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $17.22M | (m) | (m) | $-76.49M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $13.33M | (m) | (m) | $-63.89M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $8.77M | (m) | (m) | $-48.00M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $5.86M | (m) | (m) | $-34.12M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $4.43M | (m) | (m) | $-29.90M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $3.85M | (m) | (m) | $-25.02M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $3.75M | (m) | (m) | $-21.22M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $3.92M | (m) | (m) | $-22.46M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $3.69M | (m) | (m) | $-17.70M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | $3.78M | (m) | (m) | $-18.45M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $3.92M | $7.47M | (m) | $-19.70M | (m) | 52.42% | (m) | (m) | (m) |
| 2019-03-31 | $3.94M | $7.88M | (m) | $-20.14M | (m) | 49.95% | (m) | (m) | (m) |
| 2018-12-31 | $3.68M | $7.39M | (m) | $-17.69M | (m) | 49.72% | (m) | (m) | (m) |
| 2018-09-30 | $3.60M | $7.27M | (m) | $-15.65M | (m) | 49.45% | (m) | (m) | (m) |
| 2018-06-30 | $3.40M | $6.77M | (m) | $-14.70M | (m) | 50.18% | (m) | (m) | (m) |
| 2018-03-31 | $3.57M | $5.92M | (m) | $-13.09M | (m) | 60.31% | (m) | (m) | (m) |
| 2017-12-31 | $3.30M | $5.17M | (m) | $-14.42M | (m) | 63.77% | (m) | (m) | (m) |
| 2017-09-30 | $3.03M | $4.43M | (m) | $-15.14M | (m) | 68.33% | (m) | (m) | (m) |
| 2017-06-30 | $2.89M | $3.78M | (m) | $-14.88M | (m) | 76.37% | (m) | (m) | (m) |
| 2017-03-31 | $2.23M | $3.24M | (m) | $-13.38M | (m) | 68.66% | (m) | (m) | (m) |
| 2016-12-31 | $2.15M | $2.80M | (m) | $-11.10M | (m) | 76.85% | (m) | (m) | (m) |
| 2016-09-30 | $2.15M | $2.27M | (m) | $-9.13M | (m) | 94.63% | (m) | (m) | (m) |
| 2016-06-30 | $2.16M | $1.82M | (m) | $-8.96M | (m) | 118.76% | (m) | (m) | (m) |
| 2016-03-31 | $2.08M | $1.32M | (m) | $-7.84M | (m) | 157.02% | (m) | (m) | (m) |
| 2015-12-31 | $2.56M | $823.00K | $1.17M | $-7.70M | (m) | 311.66% | 142.04% | (m) | (m) |
| 2015-09-30 | $2.73M | $566.00K | (m) | $-8.42M | (m) | 481.45% | (m) | (m) | (m) |
| 2015-06-30 | $2.83M | $293.00K | (m) | $-8.38M | (m) | 964.85% | (m) | (m) | (m) |
| 2015-03-31 | $3.72M | $118.00K | (m) | $-10.47M | (m) | 3151.69% | (m) | (m) | (m) |
| 2014-12-31 | $3.94M | $51.00K | $1.22M | $-11.36M | (m) | 7731.37% | 2382.35% | (m) | (m) |
| 2014-09-30 | $4.95M | (m) | $1.59M | $-12.43M | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | $5.26M | (m) | $1.91M | $-13.16M | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | $5.33M | (m) | $1.66M | $-13.15M | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $4.91M | (m) | $2.39M | $-13.56M | (m) | (m) | (m) | (m) | (m) |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $1.50M | (m) | $390.40K | $-3.97M | (m) | (m) | (m) | (m) | (m) |
| 2012-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CVRx, Inc. (CVRX) | United States | $0.067B | -2.62 |
| FRACTYL HEALTH, INC. (GUTS) | United States | $0.075B | -1.18 |
| TELA Bio, Inc. (TELA) | United States | $0.057B | -0.82 |
| RenovoRx, Inc. (RNXT) | United States | $0.076B | -3.62 |
| Xtant Medical Holdings, Inc. (XTNT) | United States | $0.053B | |
| Spectral AI, Inc. (MDAI) | United States | $0.052B | |
| Pulmonx Corp (LUNG) | United States | $0.082B | -1.16 |
| Sensus Healthcare, Inc. (SRTS) | United States | $0.048B | -3.24 |
| SkinHealth Systems Inc. (SKIN) | United States | $0.086B | -3.17 |
| LENSAR, Inc. (LNSR) | United States | $0.087B | 2.02 |